NAGE — Niagen Bioscience, Inc.

Nasdaq · Materials · Chemicals · CIK 1386570 ·
Last close
$3.22
Market Cap
$256.45M
52W High
$5.12
52W Low
$3.12
ADV30
725,879
Next earnings
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 31,474,000 19,976,000 1,576,000 6,318,000 114,329,000 66,397,000 31,999,000
Dec 2025 33,839,000 21,704,000 2,103,000 4,132,000 106,406,000 64,636,000 29,873,000
Sep 2025 33,986,000 21,928,000 4,236,000 4,578,000 98,139,000 64,138,000 27,463,000
Jun 2025 31,117,000 20,226,000 3,185,000 3,609,000 91,525,000 60,322,000 27,330,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$13,504,000
Investing CF
$-292,000
Financing CF
$6,916,000
CapEx
$-292,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.20
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-164,528,000
Inventory
$20,424,000
Receivables
$9,741,000
ST Investments
EBIT TTM
$14,296,000
Pretax Income TTM
$18,192,000
Interest Exp TTM
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$130,416,000
EBITDA
$11,981,000
Free Cash Flow
$-1,196,500
Enterprise Value
$201,152,608
Total Cash
$66,397,000
Total Debt
$2,576,000
Shares Out
79,644,327
Trailing EPS
$0.22
Book Value
$1.03
ROE
27.1%
ROA
7.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 129,423,000 14,296,000 17,382,000 106,406,000 29,873,000 13,504,000
Dec 2024 99,597,000 7,726,000 8,550,000 68,278,000 22,184,000 12,109,000
Dec 2023 83,570,000 -5,599,000 -4,938,000 54,964,000 26,508,000 7,117,000
Dec 2022 72,050,000 -18,628,000 -16,540,000 54,057,000 25,385,000 -15,098,000

TTM Snapshot

Revenues TTM
$25,580,000
NetIncome TTM
$1,878,000
OpCashFlow TTM
$0
Assets (Latest)
$68,278,000
Forward EPS
$0.29

Peers — same industry

TickerNameMarket CapLastDaily %
LTBR LIGHTBRIDGE Corp $250.93M $7.64
NL NL INDUSTRIES INC $288.99M $5.91
CRLBF Cresco Labs Inc. $224.93M $0.63
YSG Yatsen Holding Ltd $215.57M $3.38
SNDL SNDL Inc. $312.36M $1.20

News headlines (Yahoo Finance, 1h cache)

Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biologic
2026-07-28 12:32 · Yahoo
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
2026-07-27 12:32 · Yahoo
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
2026-07-21 12:32 · Yahoo
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
2026-07-16 12:32 · Yahoo
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia
2026-07-13 12:32 · Yahoo
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
2026-07-09 12:32 · Yahoo
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
2026-07-08 12:32 · Yahoo
Implied Volatility Surging for Niagen Bioscience Stock Options
2026-07-06 15:15 · Yahoo
Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications
2026-06-19 18:20 · Yahoo
Niagen Bioscience (NAGE) Stock Sees Split Analyst Revisions As Price Targets Fall
2026-06-17 13:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.